Chlamydia Testing in Nepal — NAAT, Window Periods & Site-Matched Specimens The Commonest Curable STI — Silent, Site-Matched, and Worth Testing Correctly

Chlamydia — the Silent, Curable, Consequential Infection

Chlamydia is commonest curable STI — and most quietly consequential. ~70% of infections in women and a large fraction in men are asymptomatic; infection ascends silently to produce PID (~10–15% of untreated cases), infertility and ectopic risk that follow, and in pregnancy neonatal transmission that screening prevents.

The test is NAAT — nucleic acid amplification — ~95% sensitive on correct specimen. The "correct specimen" part is where most testing goes wrong: urine covers urethra; throat and rectal exposures need their own swabs; and a urine "negative" in a patient whose exposure included those sites is a miss, not a result.

The window is ~1–2 weeks — a test inside it is inconclusive rather than reassuring — and infection is curable with a short antibiotic course when caught. The pathway that makes testing worth doing is complete one: correct specimen, correct timing, correct treatment, partner managed.

NAAT — the Method and the Specimens

NAAT is diagnostic standard — amplifying chlamydial DNA, ~95% sensitive and specific on correct specimen. The specimen choice is clinical decision: first-catch urine for urethral exposure; cervical or vaginal swab for female genital; throat swab for oral-sex exposure; rectal swab for anal-sex exposure.

The single most common testing error is urine-only for an exposure that included other sites — a "negative" that covers only urethra while infection sits at throat or rectum. Site-matched sampling is difference between testing and actually being tested.

Why Testing — the Silent Majority

~70% of chlamydia in women is asymptomatic — infection produces no discharge, no pain, no warning — while silently ascending to uterus and tubes. In men asymptomatic fraction is smaller but still substantial. Most chlamydia is found by screening, not by symptoms.

The consequence that makes silence matter: untreated chlamydia produces PID in ~10–15% — tubal scarring that raises infertility risk ~10–20% per episode and multiplies ectopic risk. The infection is curable cheaply; complication is what is expensive — testing is what prevents second by catching first.

The ~1–2 Week Window

Chlamydia NAAT is reliable from ~1–2 weeks post-exposure — earlier testing may produce a negative that is inconclusive rather than reassuring. For a specific recent exposure, honest guidance is testing at right interval or knowing a repeat is scheduled.

Symptoms, where they occur, appear ~1–3 weeks after exposure — urethral discharge and burning in men, abnormal discharge and bleeding in women, proctitis at rectal site, pharyngitis rarely at throat — but most cases produce no symptoms at any point.

Treatment & Partners

Chlamydia is curable — a short antibiotic course (doxycycline preferred; azithromycin alternative), complete within days. Treatment without partner management is incomplete — untreated partner reinfects; partners are tested with site-matched specimens and treated.

During treatment and until partners are treated, abstain. Test-of-cure is not routine for uncomplicated chlamydia, but retesting at ~3 months is recommended because reinfection from untreated partners or new exposure is common.

Chlamydia Testing & Costs

Transparent pricing; confirm when booking.

Related Services & Guides